Prepulse Inhibition of Startle in Cocaine Dependence - 7
January 11, 2017 updated by: National Institute on Drug Abuse (NIDA)
Prepulse Inhibition of Startle in Cocaine Dependence (Human)
The purpose of this study is to assess the effects of chronic cocaine use on the acoustic startle response and on gating of this response in humans.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The objective of this study is to assess the effects of chronic cocaine use on the acoustic startle response and on gating of this response in humans.
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10010
- New York MDRU
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
Cocaine dependence. Male. Right handed. Negative urine for cocaine
Exclusion Criteria:
Positive urine for cocaine. History of head trauma. Significant medical disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Percent prepulse inhibition
|
|
Cocaine assessment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: John Rotrosen, M.D., New York MDRU
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- CPDD, 98, 99 NIDA Research Monograph Series 179, 1998 Manuscript submitted..
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 1997
Primary Completion (Actual)
April 1, 1998
Study Completion (Actual)
May 1, 1998
Study Registration Dates
First Submitted
April 18, 2001
First Submitted That Met QC Criteria
April 17, 2001
First Posted (Estimate)
April 18, 2001
Study Record Updates
Last Update Posted (Estimate)
January 12, 2017
Last Update Submitted That Met QC Criteria
January 11, 2017
Last Verified
June 1, 1998
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Pathologic Processes
- Substance-Related Disorders
- Disease
- Cocaine-Related Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Dopamine Agents
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Amantadine
Other Study ID Numbers
- NIDA-5-0013-7
- Y01-5-0013-7
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.